Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study

被引：5
|
作者：
Porta, C. G. [1 ]
Eto, M. [2 ]
Motzer, R. J. [3 ]
De Giorgi, U. F. F. [4 ]
Buchler, T. [5 ]
Basappa, N. S. [6 ]
Mendez Vidal, M. J. [7 ]
Tjulandin, S. [8 ]
Park, S. H. [9 ]
Melichar, B. [10 ]
Hutson, T. E. [11 ]
Alemany, C. [12 ]
McGregor, B. [13 ]
He, C. S. [14 ]
Perini, R. [15 ]
Mody, K. [16 ]
McKenzie, J. [16 ]
Choueiri, T. K. [13 ]
机构：
[1] Univ Bari A Moro, Interdisciplinary Dept Med, Bari, Italy
[2] Kyushu Univ, Dept Urol, Fukuoka, Japan
[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[4] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Dept Med Oncol, Meldola, Italy
[5] Thomayer Univ Hosp, Dept Oncol, Prague, Czech Republic
[6] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada
[7] Hosp Univ Reina Sofia, Maimonides Inst Biomed Res Cordoba, Dept Med Oncol, Cordoba, Spain
[8] Minist Hlth Russian Federat, NN Blokhin Natl Med Res Ctr Oncol, Dept Clin Pharmacol & Chemotherapy, Moscow, Russia
[9] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[10] Palacky Univ, Med Sch & Teaching Hosp, Dept Oncol, Olomouc, Czech Republic
[11] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dept Med Oncol, Dallas, TX USA
[12] AdventHlth Canc Inst, Dept Hematol & Oncol, Orlando, FL USA
[13] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[14] Eisai Inc, Biostat, Nutley, NJ USA
[15] Merck & Co Inc, Clin Res, Rahway, NJ USA
[16] Eisai Inc, Clin Res, Nutley, NJ USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1449MO
引用
收藏
页码：S1205 / +
页数：2
相关论文
共 50 条
  • [21] Axitinib in combination with pembrolizumab (AXI plus PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers
    Atkins, Michael
    Martini, Jean-Francois
    Plimack, Elizabeth
    McDermott, David
    Puzanov, Igor
    Fishman, Mayer
    Cho, Daniel
    Vaishampayan, Ulka
    Rosbrook, Brad
    Fernandez, Kathrine
    Tarazi, Jamal
    George, Saby
    Choueiri, Toni
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [22] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.
    Lee, Chung-Han
    Shah, Amishi Yogesh
    Hsieh, James J.
    Rao, Arpit
    Pinto, Alvaro
    Bilen, Mehmet Asim
    Cohn, Allen Lee
    DiSimone, Christopher
    Shaffer, David R.
    Sarrio, Regina Girones
    Ribe, Sara Gunnestad
    Wu, Jane
    Schmidt, Emmett V.
    Kubiak, Peter
    Okpara, Chinyere
    Smith, Alan D.
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms
    Gruenwald, Viktor
    Powles, Thomas
    Kopyltsov, Evgeny
    Kozlov, Vadim
    Gordoa, Teresa Alonso
    Eto, Masatoshi
    Hutson, Thomas
    Motzer, Robert
    Winquist, Eric
    Maroto, Pablo
    Keam, Bhumsuk
    Procopio, Giuseppe
    Wong, Shirley
    Melichar, Bohuslav
    Rolland, Frederic
    Oya, Mototsugu
    Rodriguez-Lopez, Karla
    Saito, Kenichi
    Smith, Alan
    Porta, Camillo
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 104 - 105
  • [24] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms
    Gruenwald, V
    Powles, T.
    Kopyltsov, E.
    Kozlov, V
    Alonso, Gordoa T.
    Eto, M.
    Hutson, T.
    Motzer, R.
    Winquist, E.
    Maroto, P.
    Keam, B.
    Procopio, G.
    Wong, S.
    Melichar, B.
    Rolland, F.
    Oya, M.
    Rodriguez-Lopez, K.
    Saito, K.
    Smith, A.
    Porta, C.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 25 - 25
  • [25] Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Mathew
    Stepan, Daniel E.
    Shumaker, Robert
    Schmidt, Emmett V.
    Guo, Matthew
    Dutcus, Corina
    Young, Louise
    Motzer, Robert
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 174 - 175
  • [26] A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
    Ikeda, Masafumi
    Sung, Max W.
    Kudo, Masatoshi
    Kobayashi, Masahiro
    Baron, Ari D.
    Finn, Richard S.
    Kaneko, Shuichi
    Zhu, Andrew X.
    Kubota, Tomoki
    Kralijevic, Silvija
    Ikezawa, Hiroki
    Siegel, Abby B.
    Kumada, Hiromitsu
    Okusaka, Takuji
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [27] LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
    Lwin, Z.
    Gomez-Roca, C.
    Saada-Bouzid, E.
    Yanez, E.
    Longo Munoz, F.
    Im, S-A.
    Castanon, E.
    Senellart, H.
    Graham, D.
    Voss, M.
    Doherty, M.
    Lopez, J.
    Ghori, R.
    Kubiak, P.
    Jin, F.
    Norwood, K.
    Chung, H. C.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1170 - S1170
  • [28] A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
    Llovet, J.
    Shepard, K. V.
    Finn, R. S.
    Ikeda, M.
    Sung, M.
    Baron, A. D.
    Kudo, M.
    Okusaka, T.
    Kobayashi, M.
    Kumada, H.
    Kaneko, S.
    Pracht, M.
    Mamontov, K.
    Meyer, T.
    Mody, K.
    Kubota, T.
    Saito, K.
    Siegel, A. B.
    Dubrovsky, L.
    Zhu, A. X.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [29] Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
    Grunwald, Viktor
    Powles, Thomas
    Choueiri, Toni K.
    Hutson, Thomas E.
    Porta, Camillo
    Eto, Masatoshi
    Sternberg, Cora N.
    Rha, Sun Young
    He, Cixin S.
    Dutcus, Corina E.
    Smith, Alan
    Dutta, Lea
    Mody, Kalgi
    Motzer, Robert J.
    [J]. FUTURE ONCOLOGY, 2019, 15 (09) : 929 - 941
  • [30] A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
    Zhu, Andrew X.
    Finn, Richard S.
    Ikeda, Masafumi
    Sung, Max W.
    Baron, Ari David
    Kudo, Masatoshi
    Okusaka, Takuji
    Kobayashi, Masahiro
    Kumada, Hiromitsu
    Kaneko, Shuichi
    Pracht, Marc
    Mamontov, Konstantin
    Meyer, Tim
    Mody, Kalgi
    Kubota, Tomoki
    Dutcus, Corina E.
    Saito, Kenichi
    Siegel, Abby B.
    Dubrovsky, Leonid
    Llovet, Josep M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345